RTTNews汇总五家生物科技公司的临床、商业合作、融资及监管进展，相关标的已大幅异动

Several biotech stocks were in focus Tuesday, including Bluejay Diagnostics following a federal healthcare partnership with Lovell Government Services; Pharvaris after positive Phase 3 CHAPTER-3 results; Roivant following positive Phase 2 PHocus data; PDS Biotech after announcing up to $22.55 million in PIPE financing led by Nant Capital; and Atara Biotherapeutics after an update on the anticipated resubmission of its tabelecleucel BLA.
Read on…
Bluejay Diagnostics (BJDX) announced a distribution, co-marketing and strategic partnership with Lovell Government Services to expand access to U.S. federal healthcare markets, pending FDA clearance. Under the agreement, Lovell will serve as Bluejay's exclusive distributor for federal procurement opportunities, including those with the VA, DoD, Military Health Systems and Indian Health Service. Bluejay's Symphony System is an investigational rapid diagnostic platform for sepsis triage, with its IL-6 Test designed to deliver results in approximately 20 minutes.
Currently, BJDX is trading at $1.05, up 27.40%.
Pharvaris (PHVS) reported positive topline results from the pivotal Phase 3 CHAPTER-3 study evaluating Deucrictibant XR for the prevention of hereditary angioedema attacks. The study evaluated once-daily oral Deucrictibant XR 40 mg in 85 adolescents and adults with HAE across 21 countries. The treatment reduced the mean monthly HAE attack rate by 83% versus placebo across all HAE types, while the reduction reached 87% among patients with Type 1 or Type 2 HAE.Pharvaris plans to submit an NDA to the FDA for Deucrictibant XR in the first half of 2027.
Currently, PHVS is trading at $37.82, up 7.02%.
Roivant (ROIV) reported positive Phase 2 results from the PHocus trial evaluating mosliciguat in adults with pulmonary hypertension associated with interstitial lung disease. At Week 16, mosliciguat delivered a 56.3% placebo-adjusted reduction in pulmonary vascular resistance, while improving six-minute walk distance by 35.2 meters and reducing NT-proBNP by 53.2% versus placebo. Roivant has initiated the Phase 3 PHrontier trial, which is expected to enroll approximately 375 adults with PH-ILD.
Currently, ROIV is trading at $41.35, up 18.35%.
Atara Biotherapeutics (ATRA) provided an update on the anticipated resubmission of the BLA for Tabelecleucel (tab-cel; Ebvallo), held by its partner Pierre Fabre Laboratories. Atara expects to provide a further regulatory update later this quarter. Pierre Fabre plans to resubmit the BLA with an updated dataset from the pivotal Phase 3 ALLELE study, including additional patients and longer follow-up, along with supportive data.
Currently, ATRA is trading at $10.71, up 9.73%.
Shares of PDS Biotech (PDSB) are up over 34% following the company's announcement of up to $22.55 million in PIPE financing led by Nant Capital, LLC, with participation from existing investors. The financing includes an initial closing of approximately $11.55 million and a milestone closing of up to $11 million tied to the submission of a registrational Phase 3 clinical trial protocol for PDS0301 to the FDA. The proceeds are expected to support the advancement of PDS0301 into late-stage clinical development in solid tumors.
Currently, PDSB is trading $0.29, up 33.21%.
Did you know?
Hereditary angioedema can cause recurrent episodes of swelling that may affect the face, hands, abdomen and airway. Researchers are developing oral therapies that aim to prevent these attacks by blocking key pathways involved in swelling.
For comments and feedback contact: editorial@rttnews.com
Business News
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.